Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Esophageal Squamous Cell Carcinoma, Date of authorisation: 15/09/2023, Status: Authorised
Tevimbra is a cancer medicine used to treat adults with squamous oesophageal cancer (cancer of the oesophagus, the passage from the mouth to the stomach) if the cancer is advanced, has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable). It is used after cancer treatment with platinum-based medicines has not worked well enough.
Oesophageal cancer is rare, and Tevimbra was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 13 November 2020. Further information on the orphan designation can be found on the EMA website.
Tevimbra contains the active substance tislelizumab.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
